Caplin Point Laboratories Ltd vs Novelix Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Caplin Point Laboratories Ltd is ₹ 1839 as of 06 May 15:30 . The P/E Ratio of Caplin Point Laboratories Ltd changed from 12.6 on March 2021 to 28.4 on March 2025 . This represents a CAGR of 17.65% over 5 yearsThe P/E Ratio of Novelix Pharmaceuticals Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Caplin Point Laboratories Ltd changed from ₹ 3057 crore on March 2021 to ₹ 15222 crore on March 2025 . This represents a CAGR of 37.86% over 5 yearsThe Market Cap of Novelix Pharmaceuticals Ltd changed from ₹ 5.48 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 years The revenue of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 576.45 crore as compare to the Sep '25 revenue of ₹ 564.43 crore. This represent the growth of 2.13% The revenue of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Caplin Point Laboratories Ltd for the Dec '25 is ₹ 223.35 crore as compare to the Sep '25 ebitda of ₹ 219.56 crore. This represent the growth of 1.73% The ebitda of Novelix Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Caplin Point Laboratories Ltd changed from ₹ 124.92 crore to ₹ 165.86 crore over 7 quarters. This represents a CAGR of 17.58% The net profit of Novelix Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Caplin Point Laboratories Ltd changed from 14.53 % on March 2021 to 13.43 % on March 2025 . This represents a CAGR of -1.56% over 5 yearsThe Dividend Payout of Novelix Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Caplin Point Laboratories Ltd

Promoted by Mr. C. C. Paarthipan, Caplin Point Laboratories Limited was incorporated on April 16, 1990.
The Company is presently into the business of pharmaceuticals like producing, developing and marketing wide range of generic formulations and branded products and exporting to overseas market.
Its main research and development facilities are located in Tamil Nadu, India and has a manufacturing plant in Puducherry, India.
It has over 4000+ products registrations across the globe with over 650+ pharmaceutical formulations & over 36 therapeutic sections. Caplin markets a wide spectrum of pharmaceutical formulations and therapeutic segments in 23 countries.
In addition to LATAM and Africa, it is now serving the US, European Union and other regulated markets as well.

About Novelix Pharmaceuticals Ltd

Trimurthi Limited was formerly incorporated on December 13, 1994 with the name Trimurthi Securities Ltd. The name of the Company thereafter got changed from Trimurthi Securities Ltd to Trimurthi Drugs & Pharmaceuticals Ltd. In September 2006, as per the Scheme of Arrangement, the erstwhile Trimurthi Drugs & Pharmaceuticals Ltd amalgamated with the Company.
Also, the name of the Company was changed to Trimurthi Drugs & Pharmaceuticals Ltd and again to Trimurthi Limited in May, 2016. Initially, the company was engaged in finance and investments in securities.
They ceased their operations due to the high volatility in the markets and voluntarily got de-registered as Non-Banking financial company.
Thereafter, the company explored the possibilities of entering into pharmaceutical and drug industry by way of diversification.

FAQs for the comparison of Caplin Point Laboratories Ltd and Novelix Pharmaceuticals Ltd

Which company has a larger market capitalization, Caplin Point Laboratories Ltd or Novelix Pharmaceuticals Ltd?

Market cap of Caplin Point Laboratories Ltd is 13,982 Cr while Market cap of Novelix Pharmaceuticals Ltd is 58 Cr

What are the key factors driving the stock performance of Caplin Point Laboratories Ltd and Novelix Pharmaceuticals Ltd?

The stock performance of Caplin Point Laboratories Ltd and Novelix Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Caplin Point Laboratories Ltd and Novelix Pharmaceuticals Ltd?

As of May 6, 2026, the Caplin Point Laboratories Ltd stock price is INR ₹1839.5. On the other hand, Novelix Pharmaceuticals Ltd stock price is INR ₹40.5.

How do dividend payouts of Caplin Point Laboratories Ltd and Novelix Pharmaceuticals Ltd compare?

To compare the dividend payouts of Caplin Point Laboratories Ltd and Novelix Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.